机构：[1]Shanghai Chest Hospital, Jiao Tong University, Shanghai, China[2]Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属协和医院[3]Shanghai Chest Hospital, Shanghai, China[4]Department of Medical Oncology, Cancer Hospital of Central South University, Changsha, China[5]Harbin Medical University Cancer Hospital, Harbin, China[6]Jinan Central Hospital, Shandong, China[7]The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China[8]Peking University Cancer Hospital and Institute, Beijing, China[9]Linyi Cancer Hospital, Linyi, China[10]Nantong Tumor Hospital, Nantong, China[11]Affiliated Hospital of Binzhou Medical College, Binzhou, China[12]Taizhou Hospital of Zhejiang Province, Taizhou, China台州恩泽医疗中心台州医院[13]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China[14]Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China[15]Sichuan Cancer Hospital, Chengdu, China四川省肿瘤医院[16]Department of Thoracic Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China浙江省肿瘤医院[17]Department of Thoracic Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University,, Zhuhai, China[18]The Affiliated Hospital of Qingdao University, Qingdao, China[19]Shandong Cancer Hospital & Institute, Jinan, China[20]The First Hospital of Jilin University, Changchun, China
第一作者机构：[1]Shanghai Chest Hospital, Jiao Tong University, Shanghai, China[2]Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China[3]Shanghai Chest Hospital, Shanghai, China[4]Department of Medical Oncology, Cancer Hospital of Central South University, Changsha, China[5]Harbin Medical University Cancer Hospital, Harbin, China[6]Jinan Central Hospital, Shandong, China[7]The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China[8]Peking University Cancer Hospital and Institute, Beijing, China[9]Linyi Cancer Hospital, Linyi, China[10]Nantong Tumor Hospital, Nantong, China[11]Affiliated Hospital of Binzhou Medical College, Binzhou, China[12]Taizhou Hospital of Zhejiang Province, Taizhou, China[13]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China[14]Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China[15]Sichuan Cancer Hospital, Chengdu, China[16]Department of Thoracic Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China[17]Department of Thoracic Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University,, Zhuhai, China[18]The Affiliated Hospital of Qingdao University, Qingdao, China[19]Shandong Cancer Hospital & Institute, Jinan, China[20]The First Hospital of Jilin University, Changchun, China
推荐引用方式(GB/T 7714)：
Lu Shun,Dong Xiaorong,Jian Hong,et al.Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS)[J].JOURNAL OF CLINICAL ONCOLOGY.2022,40(16):
APA：
Lu, Shun,Dong, Xiaorong,Jian, Hong,Chen, Jianhua,Chen, Gongyan...&Cui, Jiuwei.(2022).Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS).JOURNAL OF CLINICAL ONCOLOGY,40,(16)
MLA：
Lu, Shun,et al."Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS)".JOURNAL OF CLINICAL ONCOLOGY 40..16(2022)
医学